key: cord-0742896-nd1xpo6y
authors: AbdelMassih, Antoine; Gadalla, Mahenar; Hussein, Engy; Elahmady, Maryam; Zahra, Nihal; Eid, Maryam A.; Hussein, Mahinour; Hassan, Alaa A.; Abou-Zeid, Aya S.; Hassan, Aya; El Nahhas, Nadine; Emad, Nadine; Aboushadi, Nour; Ibrahim, Nourhan; Mokhtar, Sherouk; El-Husseiny, Nadine; Kamel, Aya; Hozaien, Rafeef; Menshawey, Esraa; Ismail, Habiba-Allah; Mokhles, Mokhtar; Menshawey, Rahma; Fouda, Raghda
title: The forgotten oral microbial transplantation for improving the outcomes of COVID-19
date: 2021-07-24
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2021.100923
sha: aaf341b9134c0444a8bc87bc0cf777c707fe22ae
doc_id: 742896
cord_uid: nd1xpo6y

Ever since the uncovering of the severe discrepancy of COVID-19 manifestations, irrespective of viral load, scientists have raced to locate and manage factors contributing to the genesis of a critical state. Recent evidence delineates the role of oral dysbiosis in the development of low-grade inflammation, characterized by the increase of inflammatory cytokines common to those fundamental to the development of severe COVID. Furthermore, high periodontopathic bacteria were recorded in severe acute respiratory syndrome in COVID patients as well as its common provoking comorbidities such as diabetes and hypertension. This can be explained by the immigration and elimination of oral bacteria into the airways, which, in the context of an injured lung, allows for their preferential overgrowth familiar to that causing the progression to advanced lung diseases. This is why we indicate the promising usage of oral microbiome transplantation as a treatment of the oral microbial dysbiosis, not only associated with worst outcomes of COVID-19 but also in other disorders of low-grade inflammation.

Coronavirus 2019 Disease (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was emerged in Hubei, the Chinese province in the Wuhan City, in December 2019 and rapidly showed severe spread worldwide. (1). Remarkably, patients with SARS-CoV-2 infection suffer from a wide range of symptoms. Most patients seem to have a mild form of the disease, and about 20% progress to severe disease, including pneumonia, respiratory failure, and even death. (2) Besides, the discrepancies of clinical manifestations seen in COVID-19 patients seem to be mediated by a differential immune response, not the differential viral load, as was recently claimed. (3) Even with the release of different vaccines to the market aiming for fighting the disease by building antibodies against it, unfortunately, there is still a great deal of doubt about its effectiveness, success, and its ability to offer a long-term immune cover.

Low-grade inflammation (LGI), characterized by a chronic increase in inflammatory cytokines (IL-6(Interleukin), TNF (Tumor Necrosis Factor) α and IL-1-β), is the cornerstone of all the highrisk classifications for the development of severe COVID-19. Hyperglycemia, obesity and hypertension, all features of metabolic syndrome (MetS), are believed to increase the risk of cardiovascular disease and type 2 diabetes mellitus and are all participating agents of LGI. In severe acute respiratory syndrome (SARS-CoV-2) patients, target tissues including the lungs, brain, gut and kidneys are infiltrated with proinflammatory macrophages and lymphocytes, leading to the hypercytokinaemia that supplements LGI in MetS patients. It has been found that patients with IL-6 levels of ≥80 pg/ml have a greater risk of developing respiratory failure by 22 times than that for patients with lower IL-6 level. The anatomic assembly between the oral cavity and the lungs offers plenty of opportunity for oral flora to impact lung flora in health and disease. (8) The lung is constantly subjected to a level of microbe immigration and elimination through the mucosal defence and muco-ciliary clearance. The level of microbes that migrates to the lungs is found in abundance in the upper respiratory tract and oropharynx, which has a direct form of association with the lungs. Firmicutes were found to be more evident in the diabetes patients. On the other hand, the biological specimens used in these two studies were assembled post disease diagnosis, which may have contributed to unreliable conclusions as disease condition and plan of treatment could lead to manipulating microbial profiles. Moreover, the sample size of the studies implemented was noticeably insufficient, to reach a solid conclusion. (17) In addition, Chakraborty, did not detail in his report the comorbidities in severe COVID19 patients whose BAL samples demonstrated periodontopathic stains. (18) This means that we cannot conclude, whether he coexistence of periodontopathic strains as P.

gingivalis in severe COVID-19 patients' lung microenvironment is only a coincidence due to their underlying proinflammatory comorbidities as DM, or these strains directly induce the lung damage observed in such patients or a mixture of both theories.

We, thereby, hypothesize that the replacement of oral microbiome by taxa from healthy individuals can be an efficient adjuvant therapy in patients with LGI in general, specifically COVID-19 patients, to mitigate its complications. (19, 20) Initial clinical studies were implemented to follow up patients that had ulcerative colitis and Crohn's disease, illustrating a long-term alleviation of their clinical manifestations, along with a noticeable histological and endoscopic improvement in some patients. Furthermore, a metaanalysis was conducted including nine studies showing an abatement rate of 36.2%; however, the outcomes depend on various factors as age, route of administration whether via naso-jeujenal tube, colonoscopy or enema, dose and the preparation of the donor's feaces. In particular, age is a factor that showed noticeable results, as it was proven that younger patients, with ages between 7 and 20 J o u r n a l P r e -p r o o f years old, had significantly high remission rates. Moreover, according to certain statistics, fecal microbiota transplant showed more promising results in Crohn's disease than in ulcerative colitis with remission rates of 60.5% and 22% respectively. Interestingly, the latter statistic can be taken in a reversed manner, as a study was previously done involving 15 patients with steroid-dependent ulcerative colitis that received fecal microbiota transplant via colonoscopy presenting with a preserved remission rate in 57% of the cases. 

Despite its promising results, there are multiple concerns to the generalization of fecal transplantation. One of the major concerns in the FMT is the uniformity of its delivery to patients.

Several methods have been tried, the commonest of which are via naso-jejunal tube and colonoscopy. When FMT was delivered, via the naso-jejunal tube, patients experienced high fever and C-reactive protein elevation. Moreover, cases of perforation, bleeding, and symptoms associated with anesthesia have been documented while using colonoscopy. (23) As mentioned by Nejadghaderi, the role of fecal microbiome in mediating low-grade inflammation can incite the use of FMT as a potential strategy in critical patients with COVID-19. The latter J o u r n a l P r e -p r o o f strategy was proposed in a clinical trial "NCT04251767", though it has been halted probably due to the fear of the previously mentioned complications of FMT. (24) 

Due to its reassuring outcomes, the recent utilization of oral microbiome transplantation has garnered notice over that of the fecal microbiome, which has exhibited impediments and side effects as stated before.

Aided by system-level studies of oral microbiota which identify novel molecular targets for the bacteria, OMT displays the potential of being a distinguished tool of probiotic therapies essential for the treatment of the array of human diseases affiliated to microbial dysbiosis. (25) 

Pozhitkov first proposed OMT by listing the following theoretical steps (26) 1) The acquirement of supra-gingival plaque from a caries-free donor (preferably related to the recipient),

2) The preservation of the collected plaque in saline, and

3) The transplantation of the collected plaque, by use of a nylon swab to the teeth of the recipient. 

Pozhitkov et al have conducted a study including 16 healthy white adults with clinical manifestations of periodontitis, illustrating how OMT can be a forthcoming line of therapy. The process is quite schematized, starting with the assembling of sub and supra-gingival microbiota from healthy donors, with a further screening of the samples harvested in an in-vitro antimicrobial protocol to be safely used in the recipient's oral cavity. This is followed by extensive cleaning, root planning, and administering a wide-spectrum antimicrobial agent in the form of sodium hypochlorite (NaOCl) to the recipient patient. The NaOCl sample is then neutralized by a sodium J o u r n a l P r e -p r o o f ascorbate buffer and inundated with the microbial specimen previously collected from the healthy donor with periodontitis in the regression phase.

Recently, NaOCl can be used with a moderate concentration range cautiously for the preliminary elimination of the oral microbiota prototype. The prior concentration rates of NaOCl can be deliberately neutralized, before the transplantation process for safer results. Hereby, the outcomes concluded through the previous study demonstrates that the specific oral microbiome specimens found in the healthy donors with periodontitis can be affirmatively transplanted to the diseased patients. (26) 

This generated the opportunity for a challenge between OMT and FMT due to the costeffectiveness, simplicity, the genetic stability afforded by the transplanted biofilms and the stability of the oral microbiome compared to other body niches such as gut.

Another advantage is the strong evidence of the interplay between the oral microbiome and SARS-CoV-2's ability to invade the lung mucosal barrier. Replacing the strains associated with lung predisposition to COVID-19 such as Prevotella, can minimize the ability of COVID-19 to cause significant lung damage, while the gut-lung microbial axis remains largely hypothetical.

However, further studies, clinical trials and long-term follow up are needed to understand oral microbiota dynamics and provide new insights on how a dysbiotic microbiota can be successfully replaced by a health-beneficial flora. (26, 27) J o u r n a l P r e -p r o o f

Chen et al compared in a recent study the microbial diversity of patients with periodontitis before and after treatment to healthy controls. They found that despite the improvement of the oral microbiome profile after four weeks of treatment, and the enhancement of microbial species that have a role in regulating inflammation, the microbiota profile of healthy controls still differed significantly when compared to patients after treatment. This finding shows how hypothetical OMT can be of greater efficacy when compared to classic treatment of periodontitis: -It will "clone" the microbiota profile of healthy controls and this will create a microbial niche more efficient in antagonizing low-grade inflammation -It will achieve this goal, within few hours or days compared to a minimum of four weeks in the classic treatment of periodontitis. (28) C Choosing the suitable COVID-19 candidates and the suitable donors for OMT in COVID-19 patients:

1-When to transplant, early in the course of the disease or late in established critical patients:

Owing to the predominance of a pauci-symptomatic presentation in the majority of SARS-CoV-2 patients, we suspect that OMT will implement the most beneficiary effects in patients with preexisting chronic inflammatory disorders such as diabetes or obesity. These individuals are amongst a minority of COVID patients often experiencing a detrimental delayed inflammatory response due to an ineffective unregulated early response. Moreover, their oral microbial profiles are presumed to correspond to the respiratory periodontopathic strains of critical COVID-19 patients.

Ideally, this procedure should be performed before the development of complications to halt the incriminated unregulated immune process and minimize the need for hospitalization. (29) 2-Choice of donors Several clinical trials, as well as evidence from other healthcare applications, studying the efficiency of FMT through recurrent CDI treatment, for instance, has shown disparate responses owing to a multitude of variables. Expressly, the role of microbial diversity and composition of the transplanted stools is notable. This generated the term "super-donors", alluding to the donors guaranteeing a more favourable impact in comparison to other faecal donations. Furthermore, some oral microbiota categorically improves the lung milieu of COVID-19 patients, such as Streptococcus mutans & Eubacteria. Therefore, donor supra-gingival plaques ought to be screened for predicted favourable organisms, as well for the absence of Prevotella gingivalis, associated with the worst outcome in the lung micro-environment of COVID-19 patients. Moreover, the absence of SARS-CoV-2 antigens should be ensured in the donor's saliva to prevent intensifying the recipient viral load. (30) 

In conclusion, OMT shows very promising results and upon clinical trials, it can prove that its benefits can overweigh fecal transplant due to the factors stated above and that it can help in the J o u r n a l P r e -p r o o f 

COVID-19: Current status, Challenges and Future Perspectives

The potential use of ABO blood group system for risk stratification of COVID-19

The link between obesity and COVID-19

Is it infection or rather vascular inflammation ? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19

Dental biofilms: difficult therapeutic targets

Salivary markers and coronavirus disease 2019. Cardiovasc Endocrinol Metab

Dysbiosis of salivary microbiome and cytokines influence oral squamous cell carcinoma through inflammation

Oral-lung microbiome interactions in lung diseases

The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease

The respiratory tract microbiome and lung inflammation: A two-way street

Paradigms of lung microbiota functions in health and disease, particularly, in asthma

SARS-Cov2 enables anaerobic bacteria (Prevotella, et al) to colonize the lungs disrupting homeostasis, causing long-drawn chronic symptoms, and acute severe symptoms (ARDS, septic shock, clots, arterial stroke) which finds resonance

Prevotella intermedia and periodontitis are associated with severe asthma

Increase in Salivary Cysteinyl-Leukotriene Concentration in Patients with Aspirin-Intolerant Asthma

Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. Front Microbiol

Diabetes and periodontal disease

Metagenome of SARS-Cov2 patients in Shenzhen with travel to Wuhan shows a wide range of species -Lautropia, Cutibacterium, Haemophilus being most abundant -and Campylobacter explaining diarrhea

Fecal microbiota transplantation in relapsing Clostridium difficile infection

Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis

Fecal Transplant in Inflammatory Bowel Disease

Inflammatory bowel disease. Prim Care -Clin Off Pract

The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications

Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy

Towards J o u r n a l P r e -p r o o f microbiome transplant as a therapy for periodontitis : an exploratory study of periodontitis microbial signature contrasted by oral health , caries and edentulism

Towards microbiome transplant as a therapy for periodontitis: an exploratory study of periodontitis microbial signature contrasted by oral health, caries and edentulism. BMC Oral Health

Oral microbiota transplant: a potential new therapy for oral diseases

Oral microbiota of periodontal health and disease and their changes after nonsurgical periodontal therapy

Is it infection or rather vascular inflammation ? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19

Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor